Literature DB >> 28602571

Cytoplasmic neuropilin 2 is associated with metastasis and a poor prognosis in early tongue cancer patients.

H S Ong1, S Gokavarapu2, Q Xu3, Z Tian4, J Li4, T Ji1, C P Zhang5.   

Abstract

Neuropilin 2 (Nrp2) plays an important role in regulating lymphangiogenesis. Nrp2 expression in early tongue cancer was investigated to predict lymph node metastasis and the long-term prognosis. The relationships between clinicopathological variables of cT1-T2N0 tongue squamous cell carcinoma (SCC) and overexpression of Nrp2, vascular endothelial growth factor C (VEGFC), vascular endothelial growth factor receptor 3 (VEGFR3), and semaphorin 3F (Sema3F) were analyzed. Expression levels were compared using oral SCC cell lines. The Nrp2 gene was silenced to determine the impact of Nrp2. Cytoplasmic Nrp2 overexpression predicted regional metastasis with sensitivity and specificity of 90.3% and 42.1%, respectively. Cytoplasmic Nrp2 overexpression (P<0.001) and VEGFC overexpression (P=0.006) were significantly related to regional metastasis (Student t-test). However, only cytoplasmic Nrp2 overexpression was an independent prognostic factor for both disease-free survival (DFS; P=0.008) and overall survival (OS; P=0.016) (Cox regression); the risk of recurrence was 12-times higher (P=0.015) and risk of mortality was 8-times higher (P=0.016). Co-localization of Nrp2 and VEGFC was greater within the cytoplasm of aggressive cell lines (HN12 and RCa-T). Nrp2 plays a role in tumourigenesis; VEGFC supplementation cannot rescue the biological function of Nrp2 in Nrp2-depleted cell lines. Cytoplasmic Nrp2 overexpression is associated with decreased OS and DFS. Cytoplasmic Nrp2 overexpression may be a reliable diagnostic and prognostic marker for early tongue SCC.
Copyright © 2017 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  VEGFC; head neck neoplasm; metastasis; neck dissection; neuropilin; tumourigenesis

Mesh:

Substances:

Year:  2017        PMID: 28602571     DOI: 10.1016/j.ijom.2017.03.035

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  6 in total

Review 1.  Opposing Roles of Vascular Endothelial Growth Factor C in Metastatic Dissemination and Resistance to Radio/Chemotherapy: Discussion of Mechanisms and Therapeutic Strategies.

Authors:  Christopher Montemagno; Frédéric Luciano; Gilles Pagès
Journal:  Methods Mol Biol       Date:  2022

2.  Vascular NRP2 triggers PNET angiogenesis by activating the SSH1-cofilin axis.

Authors:  Xi Luo; Jiang-Yi He; Jie Xu; Shao-Yi Hu; Bang-Hui Mo; Qiu-Xia Shu; Can Chen; Yu-Zhu Gong; Xiao-Long Zhao; Gan-Feng Xie; Song-Tao Yu
Journal:  Cell Biosci       Date:  2020-09-23       Impact factor: 7.133

3.  Semaphorin-3F/Neuropilin-2 Transcriptional Expression as a Predictive Biomarker of Occult Lymph Node Metastases in HNSCC.

Authors:  Carla Meler-Claramonte; Francesc Xavier Avilés-Jurado; Isabel Vilaseca; Ximena Terra; Paloma Bragado; Gemma Fuster; Xavier León Vintró; Mercedes Camacho
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

Review 4.  Neuropilin (NRPs) Related Pathological Conditions and Their Modulators.

Authors:  Matic Broz; Anja Kolarič; Marko Jukič; Urban Bren
Journal:  Int J Mol Sci       Date:  2022-07-29       Impact factor: 6.208

5.  Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non-small cell lung cancer.

Authors:  Anastasios Dimou; Cecile Nasarre; Yuri K Peterson; Rose Pagano; Monika Gooz; Patrick Nasarre; Harry A Drabkin; Kent E Armeson; Barry C Gibney; Robert M Gemmill; Chadrick E Denlinger
Journal:  J Thorac Cardiovasc Surg       Date:  2020-05-25       Impact factor: 6.439

6.  N2E4, a Monoclonal Antibody Targeting Neuropilin-2, Inhibits Tumor Growth and Metastasis in Pancreatic Ductal Adenocarcinoma via Suppressing FAK/Erk/HIF-1α Signaling.

Authors:  Li Wang; Lanlan Wang; Shengyu Wang; Zonglang Zhou; Zongjunlin Liu; Peilan Xu; Xian Luo; Ting Wu; Fanghong Luo; Jianghua Yan
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.